Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1368-1374

  Jungnelius, U ^a   Ringborg, U ^a   Aamdal, S ^b   Mattsson, J ^j   Stierner, U ^c   Ingvar, C ^j   Malmstrom P ^d   Andersson, R ^e   Karlsson, M ^f   Willman, K ^g   Wist, E ^h   Bjelkengren, G ^d   Westberg, R ⁱ  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j NONE

more..

Author keywords

Chemotherapy agents; Disseminated malignant melanoma; Survival; Toxicity

Indexed keywords

CISPLATIN; DACARBAZINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NORWAY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINDESINE; VOMITING;

EID: 17344382437     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00068-9     Document Type: Article

References (22)

1. 1. Comis RL, Carter SK. Integration of chemotherapy into combined-modality therapy of solid tumours: IV. Malignant melanoma. Cancer Treat Rev 1974, 1, 285-304.
2. 2. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 1976, 60, 165-176.
3. 3. Constanzi JJ. The chemotherapy of human malignant melanoma, in Constanzi JJ, ed. Malignant Melanoma, vol. 1. The Hague, Martinus Nijhoff, 1983, 259-274.
4. 4. Balch CM, Houghton A, Peters L. Cutaneous melanoma, in VT DeVita Jr, S Hellman, SA Rosenberg, eds. Cancer: Principles and Practice of Oncology, 3rd edition. Philadelphia, Lippincott, 1989, 1499-1542.
5. 5. Quagliana JM, Stephens RL, Baker SLH, et al. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group Study. J Clin Oncol 1984, 2, 316-319.
6. 6. Retsas S, Peat I, Ashford R, et al. Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma. Cancer Treat Rev 1980, 7, 87-90.
7. 7. Retsas S, Newton KA, Westbury G. Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 1979, 2, 257-260.
8. 8. Chary KK, Higby DJ, Henderson ES, et al. A phase II study with high dose cis-DDP. Wadley Med Bull 1976, 6, 37.
9. 9. Song SY, Chary KK, Higby DJ, et al. cis-Diamminedichloride platinum (II) in treatment of metastatic malignant melanoma. Clin Res 1977, 25, 411A.
10. 10. Al-Sarraf M, Fletcher W, Oishi M, et al. Cisplatin hydration with and without mannitol diureses in refractory disseminated malignant melanoma. A Southwest Oncology Group study. Cancer Treat Rep 1982, 66, 31-35.
11. 11. Buzaid AC, Murren J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 1992, 21, 205-209.
12. 12. Ringborg U, Jungnelius U, Hansson J, et al. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial, Am J Clin Oncol 1990, 13, 214-217.
13. 13. Gundersen S. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 1987, 71, 997-999.
14. 14. Verschraegen CF, Kleeberg UR, Mulder J, et al. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Cancer 1988, 62, 1061-1065.
15. 15. Pectasides D, Yianniotis H, Alevizakos N, et al. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 1989, 60, 627-629.
16. 16. Wussow PB, Hartmann F, Block KB, et al. Treatment of advanced malignant melanoma with dacarbazine, vindesine and cisplatin (DVP). Proceedings of the 4th European Conference of Clinical Oncology and Cancer Nursing 1987, 7, 968.
17. 17. Legha SS. Current therapy of malignant melanoma. Semin Oncol 1989, 1(Suppl 1), 34-44.
18. 18. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979, 48.
19. 19. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
20. 20. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II: analysis and examples. Br J Cancer 1977, 35, 1-39.
21. 21. Armitage P. Statistical Methods in Medical Research. Chichester, John Wiley and Sons, 1971.
22. 22. Cox DR. Analysis of Binary Data. London, Chapman and Hall, 1970.